ACCELERATING DRUG DISCOVERY AND DEVELOPMENT USING ARTIFICIAL INTELLIGENCE AND PHYSICAL MODELS

<p>Drug discovery and development has experienced a tremendous growth in the recent</p> <p>years, and methods to accelerate the process are necessary as the demand for effective drugs</p> <p>to treat a wide range of diseases continue to increase. Nevertheless, the majority of conventional</p> <p>techniques are labor-intensive or have relatively low yields. As a result, academia</p> <p>and the pharmaceutical industry are continuously seeking for rapid and efficient methods to</p> <p>accelerate the drug discovery pipeline. Therefore, in order to expedite the drug discovery</p> <p>process, recent developments in physical and artificial intelligence models have been utilized</p> <p>extensively. However, the overarching problem is how to use these cutting-edge advancements</p> <p>in artificial intelligence to enhance drug discovery? Therefore, this dissertation work</p> <p>focused on developing and applying artificial intelligence and physical models to accelerate</p> <p>the drug discovery pipeline at different stages. As the first study reported in the dissertation,</p> <p>the potential to apply graph neural network-based machine learning architectures</p> <p>with the assistance of molecular modeling features to identify plausible drug leads out of</p> <p>structurally similar chemical databases is assessed. Then, the capability of applying molecular</p> <p>modeling methods including molecular docking and molecular dynamics simulations to</p> <p>identify prospective targets and biological pathways for small molecular drugs is discussed</p> <p>and evaluated in the following chapter. Further, the capability of applying state-of-the-art</p> <p>deep learning architectures such as multi-layer perceptron and recurrent neural networks</p> <p>to optimize the formulation development stage has been assessed. Moreover, this dissertation</p> <p>has contributed to assist functionality identification of unknown compounds using</p> <p>simple machine learning based computational frameworks. The developed omics data analysis</p> <p>pipeline is then discussed in order to comprehend the effects of a particular treatment</p> <p>on the proteome and lipidome levels of cells. In conclusion, the potential for developing and</p> <p>utilizing various artificial intelligence-based approaches to accelerate the drug discovery and</p> <p>development process is explored in this research. Thus, these collaborative studies intend</p> <p>to contribute to ongoing acceleration efforts and advancements in the drug discovery and</p> <p>development field.</p>